Shabir Zargar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shabir Zargar has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Z. Stanton
Nationwide Children’s Hospital 2 Center for Childhood Cancer Research Columbus, Ohio
15 shared publications - Frederic G. Barr
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892
15 shared publications - Rachel A. Hoffman
Nationwide Children’s Hospital 2 Center for Childhood Cancer Research Columbus, Ohio
15 shared publications - Hana Kim
National Cancer Institute 1 Laboratory of Pathology, Center for Cancer Research Bethesda, Maryland
14 shared publications - Pawan Kumar Raut
National Cancer Institute 1 Laboratory of Pathology, Center for Cancer Research Bethesda, Maryland
14 shared publications - Salah Boudjadi
National Cancer Institute 1 Laboratory of Pathology, Center for Cancer Research Bethesda, Maryland
13 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
Functional analysis of miR-17-92 inhibition.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
Functional analysis of miR-17-92 inhibition.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
CRISPR-Cas9 knockout of P3F or MYCN suppresses MIR17HG and miR-17-92 cluster expression in FP-RMS cells.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
CRISPR-Cas9 knockout of P3F or MYCN suppresses MIR17HG and miR-17-92 cluster expression in FP-RMS cells.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Data from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
Alveolar rhabdomyosarcoma (RMS), an aggressive pediatric soft-tissue cancer, is driven by the oncogenic fusion transcription factor PAX3::FOXO1 (P3F) or PAX7::FOXO1. In a subset of fusion-positive RMS (FP-RMS) cases, amplification of the MIR17HG locus leads to overexpression of the miR-17-92 cluster of microRNAs (miRNA). However, miR-17-92 is also highly expressed in FP-RMS tumors lacking this amplification, suggesting alternative regulatory mechanisms. In this study, we show that P3F and MYCN cooperatively drive miR-17-92 expression in FP-RMS. CRISPR/Cas9-mediated knockout of P3F or MYCN in FP-RMS cell lines substantially reduced miR-17-92 expression. Using a human myoblast line or low P3F FP-RMS variant with inducible P3F or MYCN expression, P3F or MYCN alone induces minimal to low miR-17-92 expression, whereas introduction of both MYCN and P3F leads to robust activation of the miR-17-92 cluster and acquisition of oncogenic phenotypes. Chromatin immunoprecipitation sequencing revealed a P3F-binding motif located 1.84 Mb upstream of the MIR17HG promoter. CRISPR-mediated deletion of this region in the myoblast system resulted in marked reduction of miR-17-92 expression and impaired oncogenic transformation. Functional inhibition of mature miRNAs of this cluster in FP-RMS cells using miRNA-sponge constructs suppressed proliferation and transformation. In the myoblast model system, transduction studies with exogenous miR-17-92 or miRNA-sponge expression constructs indicated that miR-17-92 is necessary but not sufficient for oncogenic transformation. Implications:These findings establish a cooperative transcriptional axis in FP-RMS involving P3F and MYCN that activates MIR17HG through a distal regulatory element, thereby contributing to oncogenic behavior and uncovering a novel mechanistic vulnerability.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
Alveolar rhabdomyosarcoma (RMS), an aggressive pediatric soft-tissue cancer, is driven by the oncogenic fusion transcription factor PAX3::FOXO1 (P3F) or PAX7::FOXO1. In a subset of fusion-positive RMS (FP-RMS) cases, amplification of the MIR17HG locus leads to overexpression of the miR-17-92 cluster of microRNAs (miRNA). However, miR-17-92 is also highly expressed in FP-RMS tumors lacking this amplification, suggesting alternative regulatory mechanisms. In this study, we show that P3F and MYCN cooperatively drive miR-17-92 expression in FP-RMS. CRISPR/Cas9-mediated knockout of P3F or MYCN in FP-RMS cell lines substantially reduced miR-17-92 expression. Using a human myoblast line or low P3F FP-RMS variant with inducible P3F or MYCN expression, P3F or MYCN alone induces minimal to low miR-17-92 expression, whereas introduction of both MYCN and P3F leads to robust activation of the miR-17-92 cluster and acquisition of oncogenic phenotypes. Chromatin immunoprecipitation sequencing revealed a P3F-binding motif located 1.84 Mb upstream of the MIR17HG promoter. CRISPR-mediated deletion of this region in the myoblast system resulted in marked reduction of miR-17-92 expression and impaired oncogenic transformation. Functional inhibition of mature miRNAs of this cluster in FP-RMS cells using miRNA-sponge constructs suppressed proliferation and transformation. In the myoblast model system, transduction studies with exogenous miR-17-92 or miRNA-sponge expression constructs indicated that miR-17-92 is necessary but not sufficient for oncogenic transformation. Implications:These findings establish a cooperative transcriptional axis in FP-RMS involving P3F and MYCN that activates MIR17HG through a distal regulatory element, thereby contributing to oncogenic behavior and uncovering a novel mechanistic vulnerability.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
Cas9-induced knockout of P3F suppresses miR-17-92 transcript and mature miRNAs in FP-RMS.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
Cas9-induced knockout of P3F suppresses miR-17-92 transcript and mature miRNAs in FP-RMS.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
ChIP and chromatin interaction analysis of the distal P3F-binding site upstream of MIR17HG.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
ChIP and chromatin interaction analysis of the distal P3F-binding site upstream of MIR17HG.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
Quantification of clonogenic and focus formation assays in FP-RMS cells.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
Quantification of clonogenic and focus formation assays in FP-RMS cells.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
MiRNA levels following expression of miRNA sponges.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
MiRNA levels following expression of miRNA sponges.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
Identification of a distal P3F-binding site upstream of MIR17HG.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
Identification of a distal P3F-binding site upstream of MIR17HG.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
Effects of miR-17-92 expression in Dbt wild-type and Dbt-iP3F cells.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
Effects of miR-17-92 expression in Dbt wild-type and Dbt-iP3F cells.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
Table S1. Primer and guideRNA sequences.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma
Table S1. Primer and guideRNA sequences.